Home›Companies›Biotech & Pharma›MultiValent

MultiValent Biotherapies, Inc.

Develops targeted drug therapies for people with cancer.

No website or LinkedIn page we could confirm. Why?
Updated Nov 11, 2026·Latest SEC filing Mar 2, 2026·Suggest an edit

About MultiValent

MultiValent is a private company based in Los Altos, California, incorporated in 2025 in Delaware. It has reported $10,016,875 raised in two offerings on Form D since February 2026.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jan 9, 2026Mar 2, 2026$10,012,500target not set4$2.5MEquity, DebtRule 506(b)Form D ↗
Jan 5, 2026Feb 27, 2026$4,375fully sold11$398EquityRule 506(b)Form D ↗
Total, two offerings$10,016,875

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on MultiValent's Form D filed Mar 2, 2026.

FS
Fred Schwarzer
Executive officer, director and promoter
SS
Stephen Snowdy
Executive officer, director and promoter
Also CEO and director at Calosyn Pharma.
BK
Bruce Keyt
Executive officer, director and promoter
DS
Deborah Schwarzer
Chief Legal Officer and director

Sources

  1. SECMultiValent Biotherapies, Inc. filing history
  2. PressMultiValent Biotherapies launch announcement